Pfizer, Mylan escape another EpiPen lawsuit after judge scraps pharmacy chain's antitrust complaints

Mylan and Pfizer have spent years defending their marketing of the popular epinephrine injector EpiPen. After a busy couple of months in court, the partners have now wiped their hands of another lawsuit.

U.S. District Judge Daniel Crabtree granted Mylan's motion to dismiss an antitrust lawsuit against itself and Pfizer. Specifically, the Kansas District Court tossed out a second amended class-action complaint from KPH Healthcare Services alleging Mylan and Pfizer used anticompetitive tactics to maintain their epinephrine "monopoly," forged exclusive prescribing deals and maligned the merits of an EpiPen competitor.